Background: Coronary bifurcation lesions pose therapeutic problems during percutaneous
Introduction
Coronary bifurcation lesions pose the therapeutic challenge and are linked with higher rates of periprocedural complications as well as higher rates of in-stent restenosis and stent thrombosis [1] . Presently, provisional T-stenting (PTS) is the best approach [2, 3] . However, the optimal strategy for coronary bifurcations treatment remains a subject of debate, mainly when the side branch (SB) is large, not easily accessible or narrowed by a long lesion [4, 5] .
The aim of this study was to analyze the strategy for coronary bifurcation lesion treatment and associated clinical as well as angiographic outcomes in a large hospital in Northern Poland.
Methods

Study population and study plan
It was a prospective registry conducted between January 2012 to January 2014 in a high-volume center (> 1500 percutaneous coronary intervention [PCI] per year) in Poland (Olsztyn). Patients with stable coronary artery disease (CAD) or non-ST-segment elevation acute coronary syndrome (NSTE-ACS) were considered eligible for enrollment. The inclusion criteria were: age ≥ 18 years old, de novo coronary bifurcation lesion (including unprotected left main), main vessel (MV) diameter ≥ 2.5 mm and SB diameter ≥ 2.0 mm assessed by visual estimation. Main exclusion criteria were: ST-elevation myocardial infarction (STEMI), the inability to take dual antiplatelet therapy for 12 months, left ventricular ejection fraction ≤ 30% as well as lack of written informed consent. Institutional Review Board approved the study protocol.
Interventional procedure and concomitant medications
Procedures were performed by six independent operators. Single stent implantation in the proximal MV-distal MV across SB was the default strategy in all patients (PTS).
Bifurcation lesions were assessed according to Medina classification using an index of 1 for stenosis greater than 50% and 0 for no stenosis (visual estimation). There was no restriction regarding lesion length in patient selection. The main indication for using dedicated bifurcation stents was the ratio of proximal MV diameter to distal MV diameter > 1.2. If required, additional regular drug-eluting stents (rDES) were implanted. A stent in SB was implanted only if proximal residual stenosis was greater than 70% after balloon dilatation and/or significant flow impairment after proximal MV-distal MV stenting and/or a flow limiting dissection were noted. The implantation protocol was as follows:
1. Wiring of both branches; 2. MV predilatation and/or SB predilatation according to the operator's decision; In patients with NSTE-ACS loading dose of clopidogrel (600 mg), ticagrelor (180 mg) or prasugrel (60 mg) was given, and if needed also the loading dose of acetylsalicylic acid (ASA) was applied (300 mg). In planned procedures 72 h before PCI each patient received ASA (75 mg/24 h) and clopidogrel (75 mg/24 h). All procedures were performed in a standard way via radial or femoral access using 6 Fr or 7 Fr guiding catheters. After insertion of the arterial sheath each patient received unfractionated heparin (70-100 IU/kg). Additional was prescribed for 12 months.
All patients had troponin I (TnI), creatinine kinase (CK) and CK-MB levels examined before the procedure, 6 h and 24 h thereafter. Periprocedural myocardial infarction (MI) (type 4a) was assessed according to the third universal definition [6] .
Device description
All drug-eluting stents available in the cathlab could have been used. In this study there were regular paclitaxel-eluting stents LucChopin2 with strut thickness of 120 µm, sirolimus-eluting stents Alex with strut thickness of 70 µm or Cre8 with strut thickness of 80 µm and everolimus-eluting stents Xience with strut thickness of 81 µm and two dedicated bifurcation stents: paclitaxel-eluting BiOSS Expert ® with strut thickness of 120 µm and sirolimus-eluting BiOSS LIM ® with strut thickness of 120 µm [7, 8] .
Follow-up
Clinical follow-up was performed with office visits or telephone contact at 12 months after intervention. Adverse events were monitored throughout the study period. Follow-up coronary angiography was performed at 12 months unless clinically indicated earlier.
Endpoints
The primary endpoint was the cumulative rate of major adverse cardiovascular events (MACE) including cardiac death, MI and repeated revascularization of the target lesion (TLR). The secondary endpoints included cardiac death, all-cause death, MI, TLR and late lumen loss (LLL). All deaths were deemed cardiac unless proven otherwise.
Angiographic analysis
All angiograms were recorded after intracoronary administration of nitroglycerin (200 μg). Two orthogonal views were chosen to visualize the target lesion. A quantitative coronary angiography (QCA) was performed using dedicated bifurcation software CAAS version 5.9
(2D analysis). Catheter calibration was performed in all cases. The proximal main vessel (the artery before SB take-off), the distal main vessel (artery beyond the ostium of SB), and the SB (the smaller vessel at the point of vessel divergence) were analyzed separatelysubsegmental QCA analysis was performed according to European Bifurcation Club (EBC)
Consensus [9] . The following parameters were calculated: lesion length, reference vessel diameter (RVD), minimal lumen diameter (MLD), % diameter stenosis (%DS), acute lumen gain and LLL before and after stent implantation and/or on follow-up. All reference diameters were measured 5 mm from the end of angiographically visible plaque in all 3 segments of bifurcation without use of interpolations (user defined reference diameters). Percent diameter stenosis (using parameters from each segment) was measured for each vessel segment separately using the following formula: %DS = [1 -(MLD/RVD)] × 100% [10] .
Statistical analysis
Continuous variables were presented as mean ± standard deviation. Categorical data were presented as numbers (%). Continuous variables were compared using an unpaired Student t test, and categorical data using the χ 2 test or Fisher exact test, as appropriate. If distribution was not normal, Wilcoxon signed-rank tests and Mann-Whitney U-tests were used. P values of < 0.05 were considered statistically significant. Also, univariate and multivariate logistic regression analyses were performed. Statistical analysis was performed using R 3.0.2 for OS (R Foundation, Vienna, Austria).
Results
Baseline clinical characteristics
Between January 2012 and January 2014, a total of 152 patients were enrolled of whom 158 coronary bifurcation lesions were treated. The mean age was 62.6 ± 9.11 years and women stand for 26.3% of the population. Most patients had stable CAD (67.1%), arterial hypertension (82.2%) and dyslipidemia (88.2%). The detailed data are presented in Table 1 .
Angiographic and procedural characteristics
The bifurcation lesions were most frequently located in left anterior descending artery (LAD; 50%; Fig. 1A ), and true bifurcations (Medina type 1,1,1; 1,0,1 or 0,1,1) stand for 102 (64.6%) treated lesions. Only drug-eluting stents were deployed among which most frequently dedicated bifurcation stents were used (n = 99, 62.7%), followed by rDES (n = 59, 37.3%) ( Table 2 ).
The main procedural aspects are presented in Table 3 . All stents were successfully implanted. In 10 cases the additional stent was implanted into the SB, mainly using T-andprotrusion (TAP) or culotte techniques. In the dedicated bifurcation stent subgroup SB was stented in 4 (4.04%) cases due to significant stenosis and large diameter, whereas in regular DES 6 (10.2%) cases were registered due to significant stenosis in a large SB (n = 4) or due to flow limiting dissection (n = 2). Final kissing balloon was applied in 24.1% of procedures.
Clinical outcomes
There were 5 (3.2%) cases of periprocedural MI due to transient SB occlusion.
Additionally, there were 9 (5.7%) cases of in-hospital increase of TnI level (max 1.8 ng/mL) -however, there were asymptomatic/without electrocardiogram changes which did not require repeated angiography (MI type 4a criteria not met).
Clinical follow-up data at 12 months were available in all patients ( Figure 1B .
Similar LLL values were obtained in rDES and BiOSS LIM ® groups, whereas BiOSS Expert ® group characterized a slightly larger neointima growth. Also, when comparing LLL value significant differences in proximal MV and in distal MV, but not in SB, were observed.
Logistic regression analysis
Results of logistic regression analyses are presented in Table 5 and Table 6 for MACE and TLR, respectively. Regarding MACE rate NSTE-ACS and true bifurcation were associated with worse clinical outcome, whereas final kissing balloon was associated with better clinical outcome. Similar results were obtained when the TLR rate was analyzed.
Discussion
The main findings of this study are: 1) coronary bifurcations were mainly treated with 1 stent (PTS strategy), 2) 1-year MACE and TLR rates were 11.2% and 7.9%, respectively, 3)
clinical outcomes for dedicated bifurcation stents BiOSS and regular DES were similar, 4) optimization techniques (FKB, POT) were rarely used.
In this study the population was severely diseased, with rates of diabetes (28.3%),
prior MI (42.8%) and prior PCI (44.7%) which is higher than in other studies assessing bifurcation treatment, 11-25.7%, 19.5-46% and 11.3-37.1% [13] [14] [15] [16] [17] [18] respectively.
In recent years, a series of studies helped to characterize the coronary bifurcation anatomy, and geometric relations linking MV and SB were expressed as mathematical models such as Murray's, Finet's or Huo-Kassab's laws [11] [12] [13] . To some extent as a result EBC recommends PTS as the standard strategy for treatment of coronary bifurcation. Although there are lesions for which PTS is not the optimal approach, the need for an alternative strategy is relatively rare in most lesions [9] . Results obtained in this registry were concordant with these recommendations. Almost all bifurcations (93.7%) were treated with PTS strategy, and what is important is that 64.5% of cases were true bifurcations. As proven earlier PTS strategy ensured the best angiographic and clinical outcomes in the majority of studies [9] .
Moreover, Kim et al. as well as others showed that a 1-stent technique was better than a 2-stent technique [14, 15] .
Only 10 cases required a two-stent technique, mainly performed with TAP and culotte.
Worth stressing is the fact that all culotte procedures were performed in distal left main with the deployment of two BiOSS LIM ® stents as described previously [16] .
Predilatation of MV prior to stenting is the common approach, whereas routine SB dilation is unnecessary. Nevertheless, in the presence of severe SB ostial stenosis it should be considered. We performed MV predilatations in 82.3% cases and SB predilatations in 72.8%.
We had in mind that potential advantages of SB dilatation include increased ostial SB lumen, facilitated rewiring of the SB after stenting and avoiding rewiring and post-dilatation of the SB after implantation of the MV stent [17] .
Appropriate stent apposition in the proximal MV is achieved by POT, which is performed by dilating the proximal MV stent from the proximal stent edge to just proximal to the carina, using a short oversized balloon. POT facilitates SB access, reduces risk of accidental abluminal rewiring, lowers the risk of stent distortion by catheter collision, and enhances scaffolding at the SB ostium. Thus, POT should be considered a standard step in the bifurcation treatment. Also, FKB is the technique which optimizes the procedure [9] .
Unfortunately, in our paper rates of POT and FKB were low, 4.4% and 24.1%, respectively.
This could have been caused by the fact that only recently POT is strongly recommended by EBC, and in case of FKB -that only rarely a 2-stent technique was used where FKB is obligatory. Also, in 62.7% of cases dedicated bifurcation BiOSS stents were implanted.
Theoretically, the stepped design of the BiOSS ® delivery balloon was to ensure FKB-and POT-like effects, thus allowing operators to frequently omit this part of the procedure.
However, operators firmly believed that the BiOSS ® construction ensures those effects. As was shown in POLBOS I trial the lack of FKB/POT was associated with the worse clinical outcome and the trend in larger late lumen loss values, whereas in the NORDIC 3 study it was proved that FKB reduced angiographic side branch restenosis, especially in patients with true bifurcation lesions [18, 19] . These findings were confirmed in the MITO Registry [20] . Also worth stressing, is the fact that the negative impact of true bifurcation and positive impact of FKB on MACE and TLR rates were also confirmed in the present logistic regression analyses.
Nevertheless, the results obtained in the mentioned registry (MACE 11.2%, TLR 7.9%) were comparable or even better than in other clinical trials assessing coronary bifurcation treatment such as POLBOS I [19] , POLBOS II [21] or EBC TWO [22] .
As a kind of innovation in this study dedicated bifurcation stents were used. As was already mentioned dedicated bifurcation stents were used in 62.7% of cases. In recent years bifurcation dedicated stents were developed but majority of them did not enter routine clinical practice. In the Tryton trial, 704 patients with non-left main, true coronary bifurcation lesions were randomized to a Tryton-facilitated culotte technique or to a PTS with an everolimuseluting stent [23] . At nine months, the primary endpoint (target vessel failure) was 17.4% in the Tryton group compared with 12.8% in the PTS group. Obtained results showed that safety and efficacy reached by PTS with the latest-generation DES make the role of dedicated stents for non-left main lesions quite limited. Based on this, the EBC consensus was in favor of considering distal left main treatment due to its specific anatomic complexity, which at least in theory may benefit from technical improvements of dedicated stents [9] . This position is supported by published reports [7, [24] [25] [26] .
Limitations of the study
This registry has several limitations that should be acknowledged. First of all the sample size was relatively small and no sample size calculation was performed. Other limitations of this study are its non-randomized manner as well as other drawbacks of registry studies. Also, the variety of rDES use, the lack of intravascular ultrasound, use and the relatively low diabetes type 2 rate could be treated as the drawbacks.
Conclusions
Percutaneous coronary bifurcation treatment is safe and effective procedure, and provisional T-stenting is the preferred technique. Both regular DES as well as dedicated bifurcation stents BiOSS Expert ® and BiOSS LIM ® enabled a simple and fast bifurcation treatment option with a single stent and with comparable MACE and TLR rates.
CAD -coronary artery disease; NSTE-ACS -non-ST-elevation acute coronary syndrome; MI -myocardial infarction; PCI -percutaneous coronary intervention 
